Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.

ABSTRACT:

Background

Clinical progression rate is the typical primary endpoint measure in progressive supranuclear palsy (PSP) clinical trials.

Objectives

This longitudinal multicohort study investigated whether baseline clinical severity and regional brain atrophy could predict clinical progression in PSP-Richardson's syndrome (PSP-RS).

Methods

PSP-RS patients (n = 309) from the placebo arms of clinical trials (NCT03068468, NCT01110720, NCT02985879, NCT01049399) and DescribePSP cohort were included. We investigated associations of baseline clinical and volumetric magnetic resonance imaging (MRI) data with 1-year longitudinal PSP rating scale (PSPRS) change. Machine learning (ML) models were tested to predict individual clinical trajectories.

Results

PSP-RS patients show

SUBMITTER: Quattrone A 

PROVIDER: S-EPMC12661634 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature